Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. - Wikidata - wikimedia - TriplyDB

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

http://www.wikidata.org/entity/Q34317550

about

Executive dysfunction in Parkinson's disease and timing deficits The dopamine hypothesis of schizophrenia: version III--the final common pathway Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology Timing Tasks Synchronize Cerebellar and Frontal Ramping Activity and Theta Oscillations: Implications for Cerebellar Stimulation in Diseases of Impaired Cognition Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?Developmental origins of brain disorders: roles for dopamine Genome-wide linkage on chromosome 10q26 for a dimensional scale of major depression Epigenetics, stress, and their potential impact on brain network function: a focus on the schizophrenia diatheses Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex Parkinson disease drug screening based on the interaction between D(2) dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder The regulation of N-methyl-D-aspartate receptors by Src kinase.nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia.Animal models of schizophrenia.Bridging the gene-behavior divide through neuroimaging deletion syndromes: Velocardiofacial (22q11.2 Deletion) and Williams (7q11.23 Deletion) syndromes.Habituation and sensitization of acoustic startle: opposite influences of dopamine D1 and D2-family receptors.Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Anterior cingulate neurons represent errors and preparatory attention within the same behavioral sequence.The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?Modulators in concert for cognition: modulator interactions in the prefrontal cortex Selective effects of D- and L-govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia A dynamical systems hypothesis of schizophrenia.Dammarane Sapogenins Ameliorates Neurocognitive Functional Impairment Induced by Simulated Long-Duration Spaceflight.Neuroanatomical phenotyping in the mouse: the dopaminergic system.The puzzle of processing speed, memory, and executive function impairments in schizophrenia: fitting the pieces together Disrupted action monitoring in recent-onset psychosis patients with schizophrenia and bipolar disorder A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia.Spike-timing theory of working memory.Working memory deficits in retinoid X receptor gamma-deficient mice.Classics in Chemical Neuroscience: Aripiprazole.Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.

P2860

Q21090466-79819359-FDDB-484B-8E7D-063AB99D27B9 Q22242827-20E7F503-D4AA-4D0C-BE7F-3DE9EEC31D09 Q24534089-BDC0AAC5-E11A-49F3-B4FB-2EB1249F3A3D Q24607115-6F20272C-CDEA-4857-A4F3-4CF8FD276153 Q24633622-BD78CF05-3D0B-4529-A67D-228545B1B568 Q26738349-270C20F2-F7E9-4D98-928C-C3F64A2AF6FC Q26772771-6460BEA2-8C42-4FDE-84F5-1BA49A6F66D9 Q26864383-16A900D5-5872-4454-861C-E4B552BA503B Q27024247-674F673E-2E48-4F54-B319-FE072D1EF851 Q28384381-B7AB4729-208F-4EDA-9310-C652A09AD39B Q28388390-5C7A2DB0-237E-4CE0-9F38-8DBE1608E0B4 Q28574586-92D0FA76-C9D2-4829-9286-CF01AD951A5C Q28833697-2D61A175-649B-4DFF-A72A-7896002B11C3 Q29038503-44CFBFD1-70FE-4EE0-9924-86D186C3202D Q30010212-15AE14E8-2B0E-426B-A69D-124043757302 Q30362464-E56030A2-40CD-42CE-92CA-6F8BAE150AB4 Q30386608-C4854D31-9CD6-470B-9BA5-48BB61620B22 Q30396775-EF98C895-18FE-4444-B871-A5E8BDA1373F Q30437188-F8B038CB-3951-49F2-AF72-51CF4D3EBC81 Q30458391-3F840775-B96C-461F-8C15-1F6D3D122CB2 Q30462828-D3380929-51DC-417F-B0C8-068A7468002B Q30472917-BCDE8332-76CA-469B-8B6D-6E31BEB58078 Q30479796-FB370B69-3918-41CA-AD1F-594693495FC2 Q30482913-044C5E67-8E26-4867-B91F-101444EAF37A Q30484459-7A90F6A8-ECFA-47DA-A983-19D7BCF864F0 Q30489404-CC29F84D-7C9C-4B0B-A918-28FD633BA18D Q30489707-1863CE5B-FE73-4F09-A461-DC5ABFFDA861 Q30490231-DAF103E9-4C70-4E0F-81B3-45AD08102241 Q30493218-26F0B366-9FBE-4E5E-865C-547EA54E9B55 Q30578267-FA6F2DD8-A2B5-45A8-8D0E-CCD9DAF392F9 Q30837931-2F6028E8-7F6C-4233-BB97-50ADD03CC9BC Q30853766-40EB9E9B-3B12-4838-8C9A-93710017EF9D Q33227606-9CDE8C48-D428-4CB0-88A1-C40C37C83FD7 Q33360464-3DDE7749-F2D9-4370-AE96-286744FC56CC Q33603663-F215233A-646A-4A8D-9C9D-7CDF5190D2D4 Q33624417-D9EB71B9-8D07-4153-8CAE-B3FC6C4471AD Q33680632-F47AC1C5-CFEB-4E31-9FEC-A440FB1DDEA9 Q33841528-CCF3A877-731A-4B49-8F9E-CB44A88DD706 Q33866125-B84EB871-D57C-4864-AF40-C358DD4AD927 Q33966168-617B3402-0BA7-4532-ABEE-717EC122D859

P2860

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

http://www.wikidata.org/entity/Q34317550

description

2004 nî lūn-bûn

@nan

2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@ast

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@en

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@nl

type

label

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@ast

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@en

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@nl

prefLabel

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@ast

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@en

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@nl

P1433

Q34317550-9DCA6843-FED9-4EC4-A109-18D250580A97

P1476

Q34317550-CEA17089-323B-44E7-83EB-A2B8786D42E7

P2093

Q34317550-014B697E-5300-4F95-B1DA-1651333D1724

Q34317550-1DF3B15E-E779-4403-91D0-16B1FF4A55A1

Q34317550-26016DF3-4149-438D-AEE0-CC262F07009C

Q34317550-85767724-8DB7-4912-9FE8-23A831BC0FC4

Q34317550-AA97A01A-66C3-4F6A-80F3-CE9C92873731

P2888

Q34317550-265F939B-F6B1-4C75-A7DF-E907F3D3D524

P304

Q34317550-4BE170B6-7E2F-4FE4-8AD6-11456DAD7C1C

P31

Q34317550-096D4ABA-EC44-4CDE-8719-A36188E299FA

P356

Q34317550-5EAD046E-A11C-49A3-8DD9-556990346559

P433

Q34317550-419A420D-389D-4C13-942F-35215AFC9BAF

P478

Q34317550-344863C4-967D-4178-812F-6B2762ED010E

P577

Q34317550-A9C3667E-994B-4A51-9DBB-23E0C31FD9B5

P6179

Q34317550-7BD7D607-20FC-4DD3-8F51-7765E4197D4D

P698

Q34317550-DADC9417-A9E6-45B4-8347-294655ACD71A

P921

Q34317550-F1007430-CA3F-4EE2-8692-526654BE3431

Q34317550-e7ebf453-497e-42ef-b9fa-e79b80fa3738

P356

S00213-004-1793-Y

P1433

Psychopharmacology

P1476

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

@en

P2093

Graham V Williams

http://www.w3.org/2001/XMLSchema#string

Larry J Siever

http://www.w3.org/2001/XMLSchema#string

Patricia S Goldman-Rakic

http://www.w3.org/2001/XMLSchema#string

Stacy A Castner

http://www.w3.org/2001/XMLSchema#string

Torgny H Svensson

http://www.w3.org/2001/XMLSchema#string

P2888

s00213-004-1793-y

P304

3-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-004-1793-Y

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P577

2004-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1022278003

http://www.w3.org/2001/XMLSchema#string

P698

15118803

http://www.w3.org/2001/XMLSchema#string

P921